EUROIMMUN
Private Company
Funding information not available
Overview
EUROIMMUN is a leading, revenue-generating diagnostics company with a core focus on serological testing for autoimmune, infectious, and neurological diseases. The company leverages a broad technology platform encompassing immunofluorescence assays (IFA), ELISA, and chemiluminescence immunoassays (ChLIA), supported by automated instruments. As a subsidiary of Revvity, Inc., it benefits from global commercial scale while continuing to innovate, particularly in the high-growth area of neurological autoantibody testing.
Technology Platform
Multi-platform immunoassay developer: Indirect Immunofluorescence Assays (IFA) including cell-based assays (CBA), Enzyme-Linked Immunosorbent Assays (ELISA), and Chemiluminescence Immunoassays (ChLIA). Supported by automated instruments like UNIQO160 (IFA) and IDS i20 (random access ChLIA).
Opportunities
Risk Factors
Competitive Landscape
Operates in a competitive global IVD market dominated by large players like Roche, Abbott, Siemens, and Thermo Fisher. Holds a strong, specialized position in autoimmune and neurological serology, competing with companies like Werfen (Inova), AESKU.Diagnostics, and Mayoly Spindler. Faces increasing competition in automation from the major platform vendors.